Sotrovimab For Injection - Risk Of Treatment Failure Due To Circulation Of Sars-cov-2 Omicron Ba.2 Subvariant
Sotrovimab for Injection Recall Summary Sotrovimab, a 500 mg intravenous COVID-19 treatment, is being recalled across Canada because the Omicron BA.2 virus subvariant may not respond effectively to this medication. The recall was issued due to new safety information indicating treatment failure is possible with this particular virus variant. The product was distributed throughout Canada.
- Product
- Sotrovimab, 500 mg IV
- Reason
- New safety information - COVID
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-04-14
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/f6af4442-73a6-4150-89f3-564d9b85b0fe